Broadcast date: 28 Mar 2013
Time: 16.00-17.00 PM CET
Come and join our CEO, Attila Berces in a presentation and demo of how Omixon Target HLA is used in the analysis of targeted NGS data.
Register today!
Write an email to hajnalka.hejja@omixon.com.
Currently, there are 69 on-going clinical trials investigating HLA as a potential biomarker for safety or efficacy. It appears that beside being the most important marker in transplantation, HLA is becoming a more important biomarker for cancer therapeutic development as well. The analytical performance of NGS-based genetic tests highly depends on the bioinformatics software. Although the current false variant rate can be acceptable for research market, it is simply unsuitable for making clinical decisions.
Omixon tailors the analysis for the sequencer, amplification method, primer kit, and the characteristics of the gene target itself. This approach results in a robust and highly accurate method to identify genetic variants.
In this webinar you will learn:
- How to reduce ambiguity, increase resolution and accuracy of HLA typing using next generation sequencing
- What are the challenges for next generation sequencing data analysis for HLA
- How to determine the HLA type from NGS data directly
- How to get the highest accuracy from your NGS data
- How to use Omixon Target HLA as an HLA-typing tool
Who should attend?
- Scientists and researchers from HLA-typing labs
- Molecular biologists working with NGS
- Medical professionals working in transplantation,oncology and immunology
- Bioinformathics working in transplantaion, oncology and immunology
Presenting:
- Attila Berces, PhD, CEO of Omixon Biocomputing
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.
Reserve your webinar seat, write a mail to hajnalka.hejja@omixon.com
